BioCryst Reports First Quarter 2008 Financial Results and Clini... (oCryst.Please refer to the documents Bio...)

BioCryst Reports First Quarter 2008 Financial Results and Clinical Update

Date:5/8/2008

oCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

BIOCRYST PHARMACEUTICALS, INC.

FINANCIAL SUMMARY

Statements of Operations (Unaudited)

(in thousands, except per share)

Three Months Ended

March 31,

2008 2007

Revenues:

Collaborative and other research and

development $10,768 $9,159

Expenses:

Research and development 21,898 16,195

General and administrative 2,886 2,372

Total expenses 24,784 18,567

Loss from operations (14,016) (9,408)

Interest and other income 918 583

Net loss $(13,098) $(8,825)

Basic and diluted net loss per

common share $(0.34) $(0.30)

Weighted average shares outstanding 38,059 29,274

Balance Sheet Data (in thousands)

March 31, 2008 December 31, 2007

(Unaudited) (Audited)

Cash, cash equivalents and securities $81,166 $85,009

Receivable
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results

Post Your Comments:

BioCryst Reports First Quarter 2008 Financial Results and Clini...(oCryst.Please refer to the documents Bio...)